Nevro Corp. (NYSE:NVRO) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.59 per share.
For the full year, analysts predict revenues of $ 363.92 million, while looking forward to loss of $ 2.9 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 435.00 million ~ $ 440.00 million
Click Here For More Historical Outlooks Of Nevro Corp.
Previous Quarter Performance
Nevro Corp. came out with loss for the second quarter of $ 1.21 per share, from the revenue of $ 56.39 million. According to street consensus, NVRO was expected to report 2Q20 loss of $ 1.62 per share from revenue of $ 37.85 million. The bottom line results beat street analysts by $ 0.41 or 25.31 percent, at the same time, top line results outshined analysts by $ 18.54 million or 48.98 percent.
Stock Performance
Shares of Nevro Corp. traded up $ 5.04 or 3.37 percent on Wednesday, reaching $ 154.77 with volume of 280.60 thousand shares. Nevro Corp. has traded high as $ 154.96 and has cracked $ 149.29 on the downward trend
The closing price of $ 154.77, representing a 130.18 % increase from the 52 week low of $ 65.05 and a 11.45 % decrease over the 52 week high of $ 169.09.
The company has a market capital of $ 5.31 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 12th October 2020, maintained by SVB Leerink at Outperform rating, with $ 175.00 target price.
Conference Call
Nevro Corp. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.nevro.com
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence.
